PR Newswire
NEWARK, Calif., Nov. 25, 2020
NEWARK, Calif. , Nov. 25, 2020 /PRNewswire/ -- Protagonist Therapeutics, Inc. (NASDAQ: PTGX) today announced that Dinesh V. Patel , Ph.D., President and Chief Executive Officer, will participate in a fireside chat at the virtual Piper Sandler 32nd Annual Healthcare Conference taking place November 30 to December 3, 2020 .
The presentation will be available for registered attendees via the Piper Sandler conference site until December 3, 2020 , and will also be available November 30, 2020 , by visiting the Investors section of the Protagonist Therapeutics website at http://investors.protagonist-inc.com/ .
About Protagonist Therapeutics, Inc.
Protagonist Therapeutics is a clinical stage biopharmaceutical company that utilizes a proprietary technology platform to discover and develop novel peptide-based therapeutics to address significant unmet medical needs and transform existing treatment paradigms for patients. The Company currently has three clinical-stage assets. PTG-300 is an injectable hepcidin mimetic in development for the treatment of polycythemia vera and other blood disorders. PTG-200 is an orally delivered, gut-restricted, interleukin-23 receptor specific antagonist peptide in development for the treatment of inflammatory bowel disease, with Crohn's disease as the initial indication. In addition to PTG-200, two oral peptide interleukin-23 receptor antagonist candidates from a collaboration with Janssen Biotech, Inc., are in development and have been selected for advancement into clinical studies. PN-943 is an orally delivered, gut-restricted alpha-4-beta-7 integrin specific antagonist peptide in development for the treatment of inflammatory bowel disease, with ulcerative colitis as the initial targeted indication.
Protagonist is headquartered in Newark, California . For further information, please visit http://www.protagonist-inc.com .
View original content: http://www.prnewswire.com/news-releases/protagonist-therapeutics-to-present-at-the-virtual-piper-sandler-32nd-annual-healthcare-conference-301180347.html
SOURCE Protagonist Therapeutics, Inc.
